Some cases of hypereosinophilic syndrome and myeloproliferexamination revealed hypercellular marrow with panhyperative disorders exhibit common features and thus pose diagplasia which was predominantly myeloid. About half the grannostic and therapeutic problems. We describe a 68-year-old ulocytic cells were eosinophils and eosinophilic precursors. 
skull and chest were unremarkable. Biopsy of a skin nodule revealed granulocytic infiltrate with prominent eosinophilia and a small focal area of excess of blasts. The patient was Introduction treated with allopurinol and hydroxyurea. After an initial response to hydroxyurea, there was progression of the eosinoIn some patients diagnostic confusion between hypereosinophilia, splenomegaly and cutaneous nodules. philic syndrome (HES) and myeloproliferative syndromes like Four months after the initial presentation, he developed sevchronic myeloid leukemia (CML) with prominent eosinophilia ere pain below the left knee. There was swelling and tendercan occur because of the overlapping features. 1, 2 HES is an ness in the corresponding superomedial aspect of the left tibia. idiopathic leukoproliferative disorder characterized by susSpleen had enlarged further to 6 cm BCM but the skin lesions tained eosinophilia (Ͼ1.5 × 10 9 /l) without an apparent etiowere stable. The WBC was 50.7 × 10 9 /l with 17.2 × 10 9 /l logy or disease association and with evidence of organ eosinophils, Hb 111 g/l and platelets 122 × 10 9 /l. Radiological involvement. 3, 4 There is no specific diagnostic test for HES. examination revealed extensive erosion of medial condyle Lytic bone lesions have not been described in HES. We and upper shaft of the left tibia with an adjacent extraosseous describe a patient with hypereosinophilia who developed lytic soft tissue mass. Magnetic resonance imaging (MRI) revealed bone lesions 4 months after initial diagnosis and was treated diffuse extension of the myeloid tissue into the medullary cavias a myeloproliferative syndrome (chronic eosinophilic ties of the femur and destructive lesion of the left medial tibial leukemia) rather than as a hypereosinophilic syndrome.
condyle ( Figure 1 ). He underwent internal bone fixation and biopsy on 25 April 1996. The bone biopsy revealed an extenCase report sive myeloid infiltrate with marked eosinophilia. In focal areas there were collections of immature cells (? blasts) and no A 68-year-old symphony clarinettist presented in January megakaryocytes were recognized. Immunohistological studies 1996 with a 6 month history of lethargy, weight loss, anorexia revealed the immature blastic cells to be positive with antiglyand pruritic skin nodules. Three months prior to presentation cophorin C antibody (ab) and therefore most likely erythrohe suffered from an episode of acute gout. On examination blasts. The blast cells did not stain with antimyeloperoxidase, he looked well with enlarged liver and spleen, 2 and 4 cm CD61 (for megakaryoblasts), anti-B and T cell antibodies or below the costal margin (BCM), respectively. There were skin the lysozyme. Bone marrow examination from the iliac crest nodules measuring about 1 cm in diameter on the upper at this time revealed no change in morphology and in partichest. There was no lymphadenopathy. Laboratory investicular there was no evidence of blastic transformation. Repeat gations revealed Hb 103 g/l, platelets 169 × 10 9 /l and WBC cytogenetic and molecular studies also revealed no chromo-42.1 × 10 9 /l, with neutrophils 19.0 × 10 9 /l, eosinophils somal abnormalities or bcr-abl rearrangement, respectively. 16.8 × 10 9 /l, monocytes 1.3 × 10 9 /l and lymphocytes He was treated with irradiation to the left tibia. Subsequently 3.8 × 10 9 /l. In the blood film there were a few myelocytes and he was treated with three courses of mitozantrone and cytarametamyelocytes indicating myeloid left shift. In addition, bine which resulted in partial response. A trial of interferon some eosinophils were hypogranulated. The liver function therapy failed because of poor patient tolerance. His last treattests, renal function and LDH were normal. Bone marrow ment was a 4-day course of cytosine arabinoside. Twelve months after initial presentation, he continues to be reasonably well with WBC of 10.0 × 10 9 /l with nearly 50%
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Discussion
The features of our case, ie marked eosinophilia, splenomegaly and skin nodules are characteristic of HES. However, lytic bone lesions have not been described in this syndrome. In two previous studies 1,2 it was noted that about half the patients of HES exhibited features common to myeloproliferative disorders. The myelofibrosis and increased numbers of mature and immature neutrophils in addition to the mature and immature eosinophils which were seen in our case are features which are more like a myeloproliferative syndrome. The term chronic eosinophilic leukemia 5 (CEL) has been proposed for this category of patients. CEL is a rare and controversial entity. Its distinction from HES and CML can be difficult. These patients have clinical and laboratory features like CML but like our case lack Ph chromosome or its molecular surrogate, the bcr-abl rearrangement. Cases in the literature with Ph1 chromosome 6 or bcr-abl rearrangement are best regarded as CML with marked eosinophilia. The in vitro growth pattern of CEL cases is also similar to that seen in CML further supporting the hypothesis that these cases are a myeloproliferative disorder. 7 Lytic bone lesions which were present in our case and can occur in blastic phase of CML, have not been described in HES. The cellular infiltrate in the lytic areas of the bone in our case consisted predominantly of eosinophilic myeloid cells. The focal areas of excess of blasts could represent areas of blastic transformation. Expansion of hemopoiesis in the femoral marrow was demonstrated on MRI and radionuclide scanning. This however is unlikely to produce lytic bone lesions which are more likely the result of localized blastic transformation of CEL, analogous to that seen in CML. described in acute eosinophilic leukemia 8 but such a label would be inappropriate for our case because there was never an excess of blasts in the peripheral blood or the bone marrow. On the other hand, the label of chronic eosinophilic leukemia would be appropriate to our case despite the fact that References no cytogenetic abnormalities were demonstrated on repeat examinations. It has been suggested very recently 9 that in such cases a presumptive diagnosis of eosinophilic leukemia is ings further support the conclusion reached in this case report. discussed. in the lower extremities. He remained in cytogenetic CR off Keywords: chronic myelogenous leukemia; clonal evolution; interferon-alpha; myelodysplasia; cytogenetic response therapy until March 1994 when his platelet count dropped to 83 × 10 3 /l. Cytogenetic studies on a bone marrow aspirate showed 23 diploid metaphases and two metaphases with deletion in chromosome 5(del(5)(q13q34) ( Table 1) . Repeat Introduction cytogenetic studies in August 1994 and in October 1995 showed diploid metaphases, and improved platelet counts. In Chronic myelogenous leukemia (CML) is a clonal myeloproliFebruary 1996, the Hgb dropped to 11.7 g/dl, the WBC was ferative disorder characterized by the presence, in 90% of 3.1 × 10 3 /l with 1% blasts, and the platelets decreased to 49 patients, of a chromosomal abnormality, t(9;22), called Phila-× 10 3 /l. Bone marrow aspirate showed 3% blasts and cytodelphia chromosome (Ph). Cytogenetic clonal evolution in genetic studies showed again the del(5q) clone with evidence CML is considered a manifestation of disease progression to of clonal evolution: 44,XY,del(1)(q32), del(5)(q13q34), a more accelerated form. Its development is noted in 30 to −7,−12,−13,add(20)(p13),+mar. In April 1996, his Hgb fell to 50% of patients before the onset of blastic phase, and is asso-9.9 g/dl, and platelets to 14 × 10 3 /l; the WBC count was ciated with other manifestations of disease acceleration. [1] [2] [3] 4.6 × 10 3 /l with a differential count showing an increase in The presence of clonal evolution at diagnosis has been assothe blasts to 18%. The bone marrow had Ͻ5% blasts ciated with a poor prognosis. [4] [5] [6] Clonal evolution during the (Table 1) . Hypermetaphase fluorescent in situ hybridization course of CML may have variable prognostic implications. 7 (FISH) studies 11 done in April 1996 on 500 metaphases Treatment of CML with interferon-alpha (IFN-␣) has resulted showed no cells with Ph abnormality (0%). Reverse transcripin complete hematologic response (CHR) rates of 70 to 80%, tion polymerase chain reaction (RT/PCR) study for BCR/ABL and cytogenetic response rates of 50% which are major and was positive. Repeat RT/PCR study on 17 July 1996 was negadurable in 25 to 30%. 8 The latter patients have had the most tive. This RT-PCR was performed using a modified previously favorable outcome with IFN-␣ therapy.
8-10
described technique.
12 Briefly, 5 g of total RNA were reverse In this report, we describe three patients with Ph-positive transcribed using Superscript II RT kit (Gibco BRL) as rec-CML who achieved complete cytogenetic response ommended by the manufacturer. RT/PCR was performed using the following fluorescent primers 5′ACCGGCATGTTCCGGG-ACAAAAG'-3′, 5′-TGTTGACTGGCGTGATGTAGTTGCTTGG-3′ TAAG-3′ to amplify the BCR transcript as an internal control. Multiplex with the internal control was performed side by side replacement therapy. She remained in cytogenetic CR after IFN-␣ was discontinued. Sixty-one months after IFN-A was with a separate PCR for only the fusion transcript. In each experiment a reagent mix without DNA, positive control and discontinued, cytogenetic studies on a bone marrow aspirate showed 23/25 diploid cells and two with 46XX, 18p+. CBC negative control were included. To prevent carry-over contamination, we used Perkin Elmer (Norwalk, CT, USA) Geneshowed a WBC was 8.3 × 10 3 /l, a platelet count of 196 × 10 3 /l and a Hgb of 9.6 g/dl. Her WBC slowly rose to Amp PCR carry-over Prevention kit, in each PCR reaction dUTP substituted for dTTP and each PCR reaction mix was 32.7 × 10 3 /l over the next 3 years. Her spleen was palpable 5 to 6 cm below the costal margin and continued to enlarge treated with uracil-N-glycosidase (UNG) prior to amplification as recommended by the manufacturer. The PCR products up to 17 cm below the costal margin 36 months later, when a splenectomy was performed. Since then, her WBC has been were resolved on ABI 373 sequencer and Genescan software for quantitation (Applied Biosystems, Foster City, CA, USA). controlled with hydroxyurea. Cytogenetic studies on splenic tissue did not show the Ph abnormality, but showed 3/28 cells Southern analysis was performed on the initial presenting samples and showed rearrangement in the BCR typical for the with 45XX,−6 ( Table 2) . Hypermetaphase FISH studies on marrow in February and December 1995 showed Ph-positive t(9;22) translocation.
The patient became symptomatic later, requiring transmetaphases, respectively 5/500 (1%) and 2/374 (0.5%). fusions support with packed red blood cells and platelets every 1-2 weeks, and is alive as of December 1996. Marrow
Patient 3
studies in October 1996 showed transformation to acute myeloid leukemia, still without Ph-chromosome abnormality A 59-year-old white male was found to have an elevated WBC on a routine medical evaluation in November 1993. He was detectable. referred to our institution where his CBC showed a WBC of 78.1 × 10 3 /l, platelet count of 210 × 10 3 /l and a Hgb of 13.7 g/dl. The WBC differential, peripheral blood smear and
Patient 2
bone marrow aspiration were consistent with the diagnosis of CML. Bone marrow cytogenetic studies showed 100% Ph-A 62-year-old female was found to have splenomegaly on routine physical examination in March 1984. Her CBC showed positive metaphases. He was started on IFN-␣ 5 mu/m 2 /day and ara-C 10 mg/day subcutaneously, achieving a cytogenetic a WBC of 45.3 × 10 3 /l, a Hgb of 11.5 g/dl and a platelet count of 580 × 10 3 /l. The smear and the bone marrow were CR after 6 months of treatment. A 50% reduction in the dose of ara-C was necessitated by cytopenia. In August 1995, he consistent with CML and the cytogenetic studies on a bone marrow aspirate showed t(9;22)(q34;q11) in all metaphases.
developed hypothyroidism, requiring thyroid hormone replacement therapy. In November 1995, bone marrow cytoThe patient was treated with IFN-␣ 5 mu/m 2 daily, achieving a CHR after 2 months, and a cytogenetic CR after 13 months genetic studies showed 17 diploid cells and three cells with deletion in chromosome 11 (11q21-23). His counts remained of therapy. She was continued on therapy for 18 more months (total treatment duration 31 months) when IFN-␣ was disconwithin acceptable limits and the treatment has been continued since then (Table 3) . Cytogenetic studies in May 1996 showed tinued due to the development of Coombs-positive autoimmune hemolytic anemia; she also had concomitant autodisappearance of the clonal evolution, and hypermetaphase FISH studies showed 2/400 Ph-positive cells (0.5%). immune-mediated hypothyroidism which was treated with Rx, treatment; IFN-α, Interferon alpha; ara-C, cytosine arabinoside; mu, million units; sq, subcutaneously; WBC, white blood cell count, Hgb, hemoglobin, Ph+, Philadelphia positive; met, metaphases; FISH, fluorescent in situ hybridization.
Discussion
IFN-␣ and ara-C which later disappeared, but remains with normal counts on therapy and in Ph cytogenetic CR. Several possible explanations can be related to the emergIn this report, we describe three patients with Ph-positive CML who achieved a durable cytogenetic CR with IFN-␣ therapy, ence of new clones in patients with CML in cytogenetic CR including: (1) changing the natural history of the disease; but developed unrelated new clones, with cytogenetic abnormalities, 5q13q34, 18p11, and 11q21q23 while still in cyto-(2) treatment-related clonal emergence; and (3) underlying stem cell disease, associated with Ph-positive as well as genetic CR of their CML disease. Two of the patients, had been off IFN-␣ treatment for 36+ and 60+ months, respectother abnormalities.
Changing the natural course of a particular disease may ively. Both patients had, in addition, a myelodysplastic syndrome in the first case, and myeloproliferative syndrome in unmask previously unknown patterns of disease evolution, which would become evident because of survival prothe second case, but the bone marrow cytogenetic studies did not show the Ph abnormality. The third patient developed the longation. The question always arises as to whether the new findings are part of the disease process or treatment-induced. new cytogenetic abnormality while still on treatment with For example, prior to the advent of effective therapy with hydvs hydroxyurea therapy in ongoing randomized trials.
21,22
While such complications have not been reported at a higher roxyurea, busulfan and other agents, most patients with Phpositive CML (85%) expired from the complications of chronic frequency in studies of IFN-␣ therapy in lymphoma, myeloma, or other solid tumors, an analysis of their comparative timephase disease. Controlling the chronic phase of CML with these agents resulted in the observation that most patients dependent frequency in the CML randomized trials would be important. developed 'acute leukemia' or blastic phase and died of its complications. It was initially thought that the blastic phase Since Ph-positive CML is a stem cell disorder, another possibility is that the selective Ph-suppression obtained with IFNmay be related to hydroxyurea and busulfan therapy. While the leukemogenic potential of busulfan is established and that ␣ therapy may allow the evolution and expansion of other suppressed clones existing simultaneously or arising in time. of hydroxyurea is questionable, it is now well known that the blastic phase of CML is part of the natural evolution of the This hypothesis may also explain the divergent cytogenetic abnormalities observed in our patients, as opposed to consistdisease in most patients, rather than therapy-related. Similarly, patients with hairy cell leukemia treated with effective therapy ent particular chromosomal aberrations attributable to therapy. (IFN-␣ or nucleoside analogues) were observed to develop second malignancies. 13, 14 In summary, this report describes three unusual cases of patients with Ph-positive CML who developed new clonal With IFN-␣ therapy, a change in the course of CML was achieved: survival prolongation in the average population, but cytogenetic disorders, two of them with clinical significance, while in cytogenetic CR of Ph-positive disease. These findings most importantly among patients achieving major cytogenetic responses. In this report, three patients in the latter group stress the importance of long-term monitoring of patients with CML or other cancers who undergo new treatments that alter developed new clonal abnormalities, two of them with significant myeloid disorders, myelodysplastic syndrome and the previously charted course of their disease, in order to observe potential disease or new treatment-related manifesmyeloproliferative syndrome. Shepherd et al 15 reported the development of clonal disease in Ph-negative cells of two tations. patients with CML on IFN-␣ therapy but who were not completely Ph-negative. The first patient developed trisomy 8 in 30% of Ph-negative metaphases (70% were still Ph-positive) References following busulfan-induced aplasia and only 3 weeks of IFN-␣ therapy. She remains in CR following allogeneic bone marrow
LETTER TO THE EDITOR

Highly complex chromosomal abnormalities in plasma cell leukemia as detected by FISH technique
During the last decade, increasing attempts have been made formamide/2 × SSC (pH 7.0), 2 × SSC/0.1% NP-40 at 45°C. to find nonrandom chromosomal abnormalities to human
The probes were spectrum orange or spectrum green fluoromalignancies. This approach has been most successful for phore labeled and the hybridization included unlabeled comhematological diseases, some of which have well established petitor human Cot-1 DNA. DAPI/phenylenediamine dihydrospecific chromosomal markers, such as in CML, ALL and chloride was used as a counter stain. The images were ANLL.
1 Although belonging to this group of neoplasms, cytocaptured on an Oncor Imaging system with a three-chip genetic studies on multiple myeloma (MM) and plasma cell cooled camera (Oncor, Gaithersburg, MD, USA). leukemia (PCL) have been mostly unsuccessful. This is mainly A total of 25 metaphases were analyzed: five cells were due to the slow plasma cell turnover compared to nonmalignormal, whereas 20 cells consisted of one hypodiploid clone nant bone marrow cells, which accounts for the high rate of showing multiple abnormalities (Figure 1 ). In particular, the normal karyotypes found in these two disorders. 2 We report a most significant finding was an add(14)(q32) which is the most case of PCL where multiple chromosomal abnormalities were consistent structural rearrangement reported in MM and found in the patient's bone marrow. Fluorescence in situ PCL. 2, 4, 5, 6 It is to be noted that the breakpoint is on band q32 hybridization (FISH) technique was employed to unveil the on chromosome 14, where the Ig heavy chain gene locus is complex nature of the chromosomal abnormalities as routine located. 1 By FISH technique using whole chromosome paintcytogenetics was an unsuccessful attempt.
ing probes for chromosomes 14 and 16, we were able to A 68-year-old Caucasian female presented in January 1996 identify the donor on 14q as being chromosome 16 in our with fatigue, confusion, dehydration, weight loss and low case (Figure 2 ). To the best of our knowledge, this is the first back pain. She was known to have been hypertensive for 4 report of a t(14;16) in MM or PCL. The importance of such a months. Physical examination was notable for lethargy and finding resides in the fact that t(11;14)(q13;q32) has often the presence of multiple ecchymoses on the upper and lower been identified in MM and PCL, 2,4,5 which may lead to specuextremities. The patient was anemic and thrombocytopenic lation that these two neoplasias have the same molecular basis with a hemoglobin level of 6.2 g/dl and a platelet count of as B-CLL. However, identification of other donor chromo-22 000. Her leukocyte count was 12 900 with a shift of the somes such as chromsomes 1, 6 4 but with blood smear showed marked rouleaux formation as well as variable breakpoints. It is to be noted that the VH genes have immature plasma cells and many atypical lymphocytes. Serum been localized on that same chromosome. 4 Other hot spots protein electrophoresis showed a biclonal IgG/IgA gammopaof chromosomal abnormalities in plasma cell malignancies, thy and kappa light chains were present in the urine. Biopsy such as chromosomes 17 2 and 19 4, 6 are also found to be of the bone marrow revealed sheets of atypical plasma cells. implicated in rearrangements in our study. Interestingly, a The diagnosis was PCL. The patient was treated with melbreakpoint at band q24 of chromosome 12 was noticed in our phalan and prednisone, with no response. She expired in March 1996, likely secondary to sepsis. A bone marrow samcase as well as in previous studies but with no comments on ple was set for cytogenetic evaluation prior to the initiation significance. 5, 6 Multiple complex changes of chromosome 1 of chemotherapy.
are also noted in our case. Chromosome 1 is the most comCytogenetic analysis was performed from a bone marrow monly implicated in structural abnormalities in MM 2,4,5,6 but specimen using routine protocol. 3 FISH technique was carried the absence of specific breakpoints leads to the hypothesis out employing whole chromosome painting probes (WCP) for that these changes could just be secondary events in the evolchromosomes 1, 12, 14, 16, 17 and 19 (Gibco/BRL, Gaithersution of tumor progression. However, trisomy 1q and partial burg, MD, USA). All procedures were as recommended by the monosomy 1p are recurrent findings 5, 6 and are confirmed in manufacturer. Briefly, slides were air dried for at least 2 our case. Finally, numerical aberrations observed in our days prior to denaturation, then denatured in 70% patient, such as monosomy 13, 17 and X are consistent, as formamide/2 × SSC at 70°C for 10-15 s each and passed noted in most previous studies. 2, 4, 5 through an ethanol dehydration series. All probes were In conclusion, the presence of all these recurrent chromodenatured for 10 min at 70°C prior to hybridization and somal abnormalities has become one more parameter in the hybridized at 37°C in a moist chamber overnight. The process of zeroing in on a specific chromosomal and genetic stringency of the post-hybridization washes was 50% basis for plasma cell malignancies. Nevertheless, any significance of the t(14;16) present in our patient still remains to be determined by additional cases which should be reported.
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Figure 1
Representative karyotype demonstrating multiple chromosomal abnormalities from the patient. (1) 
